MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call ...

合作核心内容 - MACOM与HRL实验室达成协议 获得HRL专有的40nm T3L GaN-on-SiC工艺技术的授权和制造权 [1] - 双方将合作快速将该专有半导体工艺从HRL工厂转移到MACOM的一家美国可信代工厂 [1] - MACOM将获得基于T3L工艺制造产品的独家授权 [1] 技术细节与优势 - T3L工艺采用专有的外延结构和先进的栅极设计 使其在毫米波频率下具有领先的性能和更高的可靠性 [2] - 该工艺非常适用于支持商业和国防应用 [2] - T3L是业界最先进的高频半导体工艺之一 [4] 技术开发背景 - T3L工艺由HRL在美国国防部副部长办公室的STARRY NITE项目和DARPA的DREaM项目下 以及HRL的额外资金支持下成熟起来 [3] - HRL由波音和通用汽车共同拥有 长期被公认为射频和微波GaN-on-SiC工艺技术研发领域的先驱 [2][6] 公司业务与影响 - MACOM为电信 工业与国防以及数据中心行业设计和制造高性能半导体产品 每年为超过6000家客户提供服务 [5] - 此次合作将使MACOM及其客户受益于T3L工艺的成果 预计将增强公司现有产品组合并加速其路线图的执行 [4] - 与MACOM的合作展示了HRL在开发和验证技术概念 并将其转化为生产方面的专业知识 [4]

Landsbankinn hf. announced today the results of a tender offer published on 27 October 2025 where holders of its EUR 2027 notes (ISIN: XS2679765037) were invited to tender their notes for purchase by the Bank against a cash payment. The tender offer was subject to the terms and conditions outlined in the tender offer memorandum. The Bank received valid tenders of EUR 281,590,000 of which all were accepted. Joint lead managers are ABN AMRO Bank, BofA Securities Europe, Natixis and NatWest Markets. Further in ...

Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S. Attachment 11_2025_Annual_Report_2024-25 ...

行业趋势与市场验证 - 亚马逊CEO Andy Jassy在Q3财报电话会中将“AI和智能体商务”描述为在线购物的下一个重大转型[1] - 全球最大的电子商务平台的表态验证了智能体商务作为零售业未来的趋势[2] - 智能体商务被视为下一个万亿美元级别的市场浪潮[4] 公司技术与架构优势 - 公司自2016年起就开始为智能体商务时代构建技术基础[1] - 公司拥有近十年积累的智能体商务架构 该架构包含能够代表消费者进行自主推理、决策和交易的人工智能体[2] - 公司的智能体商务架构包含三层基础 具体为SmartPay数字资产支付通道 Subsquid实时区块链数据骨干网 以及Brainpowa专有推理引擎[7] - 公司的生态系统已为多个大陆的主要零售商和支付提供商提供实时部署 并与微软和谷歌等合作伙伴集成[3] 市场地位与竞争优势 - 公司在智能体商务领域拥有先行者优势和深厚的人工智能基础设施[4] - 公司被定位为自主数字商务新时代的类别领导者[4] - 公司正在定义万亿美元智能体商务经济的基础设施层[4] - 公司首席执行官表示 公司在构建大规模智能体购物所需的架构、数据系统和AI推理引擎方面已领先多年[3]

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program ex ...

Third quarter net income of $17.7 millionThird quarter Adjusted EBITDA of $39.3 millionDredging backlog of $934.5 million at September 30, 2025 HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Revenue was $195.2 millionTotal operating income was $28.1 mil ...

NEW YORK and SEOUL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- K Wave Media (Nasdaq: KWM), a Korean cultural innovation and digital asset company, today announced the appointment of Yong (Howard) Fang as its new Chief Financial Officer (CFO). Fang brings extensive financial and operational expertise to K Wave Media, with a proven track record in capital markets, investor relations, and global financial strategy. Over his career, he has played a pivotal role in helping take two companies public—via both initial publi ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has be ...

Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators, oncology and statistical experts LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will host an R&D Day for investors ...